

| PATIENT INFORMATION | | | | | | | | | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------------------|
| LAST NAME | | FIRST NAME | | MIDDLE NAME | | DATE OF BIRTH | | | | | |
| | | | | | | MO | DAY | YR | | | |
| ADDRESS | | | | CITY | | STATE | | ZIP CODE | | | |
| TELEPHONE | | EMAIL | | ENGLISH SPEAKING? <input type="checkbox"/> Yes | | DIAGNOSIS DATE | | | | | |
| () | | | | <input type="checkbox"/> No (Lang. _____) | | MO | DAY | YR | | | |
| SEX ASSIGNED AT BIRTH | | GENDER IDENTITY | | | ETHNICITY | | RACE (check all that apply) | | | | |
| <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Intersex <input type="checkbox"/> Refused | | <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Nonbinary/Genderqueer | | | <input type="checkbox"/> Transgender MTF <input type="checkbox"/> Transgender FTM <input type="checkbox"/> Other: _____ | | <input type="checkbox"/> Hispanic <input type="checkbox"/> Non-Hispanic <input type="checkbox"/> Unknown | | <input type="checkbox"/> White <input type="checkbox"/> Black <input type="checkbox"/> American Indian / Alaskan Native <input type="checkbox"/> Native Hawaiian / Other Pacific Islander <input type="checkbox"/> Asian <input type="checkbox"/> Other <input type="checkbox"/> Unknown | | |
| CURRENTLY PREGNANT? | | REASON FOR EXAM (check one) | | GENDER OF SEX PARTNERS (check all that apply) | | | HIV STATUS *Submit HIV/AIDS Case Report | | CURRENTLY ON PrEP? | | |
| <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown <input type="checkbox"/> NA | | <input type="checkbox"/> Exposed to Infection <input type="checkbox"/> Symptomatic <input type="checkbox"/> Routine Exam (No Symptoms) | | <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Nonbinary / Genderqueer | | | <input type="checkbox"/> Transgender MTF <input type="checkbox"/> Transgender FTM <input type="checkbox"/> Other <input type="checkbox"/> Unknown | | <input type="checkbox"/> Previous positive <input type="checkbox"/> New HIV diagnosis at this visit* <input type="checkbox"/> Negative HIV test at this visit <input type="checkbox"/> Did not test (unknown status) | | <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA |
| DIAGNOSIS - DISEASE | | | | | | | | | | | |
| GONORRHEA (lab confirmed) | | | | | SYPHILIS | | | | | | |
| DIAGNOSIS (check one) | | SITES (all that apply): | | TREATMENT (check all prescribed): | | | STAGE (check one): | | | | |
| <input type="checkbox"/> Asymptomatic <input type="checkbox"/> Symptomatic, Uncomplicated <input type="checkbox"/> Pelvic Inflammatory Disease <input type="checkbox"/> Ophthalmia <input type="checkbox"/> Disseminated <input type="checkbox"/> Other Complications: _____ | | <input type="checkbox"/> Cervix <input type="checkbox"/> Urethra <input type="checkbox"/> Urine <input type="checkbox"/> Rectum <input type="checkbox"/> Pharynx <input type="checkbox"/> Vagina <input type="checkbox"/> Ocular <input type="checkbox"/> Other: _____ | | <input type="checkbox"/> Ceftriaxone: <input type="checkbox"/> 250 mg <input type="checkbox"/> 500 mg <input type="checkbox"/> 1 g <input type="checkbox"/> Cefixime: <input type="checkbox"/> 400 mg <input type="checkbox"/> 800 mg <input type="checkbox"/> Azithromycin: <input type="checkbox"/> 1 g <input type="checkbox"/> 2 g <input type="checkbox"/> Doxycycline: <input type="checkbox"/> 100 mg BID x 7 days <input type="checkbox"/> Gentamicin: <input type="checkbox"/> 240 mg <input type="checkbox"/> Gemifloxacin: <input type="checkbox"/> 320 mg <input type="checkbox"/> Other: _____ | | | <input type="checkbox"/> Primary (Chancere, etc.) <input type="checkbox"/> Secondary (Rash, etc.) <input type="checkbox"/> Early Latent (< 1 year) <input type="checkbox"/> Unknown Duration or Late <input type="checkbox"/> Congenital | | | | |
| Date Tested: _____ | | | | Date Prescribed: _____ | | | MANIFESTATIONS (check all that apply): | | | | |
| | | | | | | | <input type="checkbox"/> Neurologic <input type="checkbox"/> Otic <input type="checkbox"/> Ocular <input type="checkbox"/> Tertiary | | | | |
| CHLAMYDIA (lab confirmed) | | | | | | | | | | | |
| DIAGNOSIS (check one) | | SITES (all that apply): | | TREATMENT (check all prescribed): | | | TREATMENT (check one): | | | | |
| <input type="checkbox"/> Asymptomatic <input type="checkbox"/> Symptomatic, Uncomplicated <input type="checkbox"/> Pelvic Inflammatory Disease <input type="checkbox"/> Ophthalmia <input type="checkbox"/> Other Complications: _____ | | <input type="checkbox"/> Cervix <input type="checkbox"/> Urethra <input type="checkbox"/> Urine <input type="checkbox"/> Rectum <input type="checkbox"/> Pharynx <input type="checkbox"/> Vagina <input type="checkbox"/> Ocular <input type="checkbox"/> Other: _____ | | <input type="checkbox"/> Azithromycin: <input type="checkbox"/> 1 g <input type="checkbox"/> Doxycycline: <input type="checkbox"/> 100 mg BID x 7 days <input type="checkbox"/> Levofloxacin: <input type="checkbox"/> 500 mg daily x 7 days <input type="checkbox"/> Other: _____ | | | Bicillin L - A: <input type="checkbox"/> 2.4 MU IM x 1 <input type="checkbox"/> 2.4 MU IM x 3 Doxycycline: <input type="checkbox"/> 100 mg BID x 14 days <input type="checkbox"/> 100 mg BID x 28 days Benzathine <input type="checkbox"/> 50,000 units/kg IM x 1 PCN-G: <input type="checkbox"/> 50,000 units/kg IM x 3 Aqueous <input type="checkbox"/> 18-24 MU/day IV Crystalline for 10-14 days Penicillin G: _____ Other: _____ | | | | |
| Date Tested: _____ | | | | Date Prescribed: _____ | | | Date Prescribed: _____ | | | | |
| HERPES SIMPLEX | | | | | OTHER DISEASES | | | | | | |
| DIAGNOSIS | | LABORATORY CONFIRMATION | | | | | | | | | |
| <input type="checkbox"/> Genital (initial infection only) <input type="checkbox"/> Neonatal | | <input type="checkbox"/> Yes <input type="checkbox"/> No | | <input type="checkbox"/> Chancroid <input type="checkbox"/> Granuloma Inguinale <input type="checkbox"/> Lymphogranuloma Venereum | | | | | | | |
| | | | | | | | Date Prescribed: _____ | | | | |
| PARTNER TREATMENT PLAN (check one or more options) | | | | | | | | | | | |
| Providers should manage partner treatment by either treating partners in-person or by prescribing medication for patients to give to their sex partners (see side 2 for additional information). | | | | | | | | | | | |
| <input type="checkbox"/> In-person evaluation - Number of partners treated following medical evaluation: _____ | | | | | Turn over for Partner Treatment Plan Instructions | | | | | | |
| <input type="checkbox"/> Patient-delivered treatment* - Number of partners for whom provider prescribed or provided expedited partner therapy (EPT) medication pack to be delivered by the patient to their partner(s): _____ *Patient-delivered treatment is not recommended for men who have sex with men or patients with syphilis | | | | | | | | | | | |
| REPORTING CLINIC INFORMATION | | | | | | | | | | | |
| DATE | | FACILITY NAME | | | DIAGNOSING CLINICIAN | | | | | | |
| ADDRESS | | | | CITY | | | STATE | | ZIP | | |
| PERSON COMPLETING FORM | | | | TELEPHONE () | | | EMAIL | | | | |

Thank you for reporting an STD. All information will be managed with the strictest confidentiality.

PRIVILEGED AND CONFIDENTIAL COMMUNICATIONS: The information contained in this message is privileged, confidential, or otherwise exempt from disclosure and is intended solely for the use of the individual(s) named above. If you are not the intended recipient, you are hereby advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received this facsimile in error, please immediately notify the sender by telephone and destroy the original facsimile.

PARTNER MANAGEMENT PLAN INSTRUCTIONS

Gonorrhea or Chlamydia Infection: Partner Treatment

All partners should be treated as if they are infected.

The Washington State Department of Health strongly encourages providers to take responsibility to ensure partner treatment for heterosexuals, by examining and treating all patient's sex partners from the previous 60 days.

If an examination is not possible, providers should offer medication for all sex partners whom patients are able to contact.

Snohomish Health District may be able to provide free medication to your patient to give to his or her partner(s), if resources permit. Please contact the health district to report cases and inquire about partner management resources, possibly including EPT medications.

Snohomish Health District recommends you refer all **MSM patients** and all **patients with syphilis or newly diagnosed HIV** to the health district for help notifying partners to ensure that partners receive medication, the opportunity to test for HIV, syphilis, gonorrhea, and chlamydia, and evaluation for HIV Pre-Exposure Prophylaxis (PrEP). Please inform the patient that the health district will contact them to assist with partner notification.

Although the health district requests that you refer patients with these risks to us, we also ask that you make every effort to help patients assure that their partners are treated.

Complete the partner management plan on the Confidential Sexually Transmitted Disease Case Report FAX form to define a partner management plan.

For copies of this case report or questions on how to fill it out, call the **Snohomish Health District, 425.339.5261**.

Other STDs: Partner Treatment

All patients with infectious syphilis, chancroid, LGV, or granuloma inguinale are routinely contacted by public health staff. Patients diagnosed with genital herpes should be advised to notify their sex partners and should be informed that their partners should contact their provider for testing. Per CDC treatment guidelines, sex partners of patients who are diagnosed with early syphilis (primary, secondary, or early latent) and may be incubating disease should be treated regardless of test results. Alternative treatment for penicillin allergy among non-pregnant patients, such as an appropriate dosage of doxycycline, can also be found in the guidelines.

RECOMMENDED REGIMENS FOR ANTIMICROBIALS LISTED ON REPORTS*

GONORRHEA -- Uncomplicated

Ceftriaxone 250 mg IM as a single dose **PLUS** Azithromycin 1g PO as a single dose

Alternatives:

Cefixime 400 mg PO as a single dose **PLUS** Azithromycin 1g PO as a single dose **OR**

For beta-lactam allergic patients:

Azithromycin 2g PO as a single dose **PLUS** Gentamicin 240mg IM as a single dose **OR** Gemifloxacin 320mg PO as a single dose

CHLAMYDIA -- Uncomplicated

Azithromycin 1g PO as a single dose **OR**

Doxycycline 100 mg PO BID for 7 days

Alternatives:

Erythromycin (base) 500 mg PO QID for 7 days **OR**

Ethylsuccinate 800 mg PO QID for 7 days **OR**

Ofloxacin 300 mg PO BID for 7 days **OR**

Levofloxacin 500 mg PO for 7 days

SYPHILIS -- PRIMARY, SECONDARY, OR EARLY LATENT (<1 YEAR)

Benzathine penicillin G 2.4 million units IM in a single dose

SYPHILIS -- LATE OR UNKNOWN DURATION

Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals

* Refer to "STD Diagnostic and Treatment Guidelines" or the Centers for Disease Control and Prevention's (CDC's) website (<http://www.cdc.gov/std/tg2015/default.htm>) for further information on treating pregnant patients, infections of the pharynx, treatment of infants and other details.

DOH 347-102, updated. For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).